Zilucoplan
- Generic Name
- Zilucoplan
- Brand Names
- Zilbrysq
- Drug Type
- Small Molecule
- Chemical Formula
- C172H278N24O55
- CAS Number
- 1841136-73-9
- Unique Ingredient Identifier
- YG391PK0CC
- Background
Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. In October 2023, zilucoplan gained its first FDA approval for the treatment of generalized myasthenia gravis.
- Indication
Zilucoplan is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
- Associated Conditions
- Generalized Myasthenia Gravis
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath